Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03404531 Recruiting - HIV Infections Clinical Trials

Project Minority AIDS Prevention: Reaching Black and Hispanic MSM About PrEP and TasP Using Social Media

MAP
Start date: November 10, 2017
Phase: N/A
Study type: Interventional

This project has the potential to improve the implementation science of treatment as prevention and pre-exposure prophylaxis uptake as a public health strategy for reducing new HIV infections in the United States. We will develop and pilot test an intervention that combines messages sent over social media plus a newly developed interactive website specifically developed by and for Black/African American and Hispanic/Latino MSM to encourage treatment as prevention and pre-exposure prophylaxis use. Findings from this research can guide policy guidelines and recommendations for treatment as prevention and pre-exposure prophylaxis uptake for high-risk groups.

NCT ID: NCT03399903 Recruiting - HIV-1-infection Clinical Trials

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

Start date: May 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

An open label study will be performed on 60 people with HIV infection who are maintained on effective treatment with antiretroviral drugs.

NCT ID: NCT03397420 Recruiting - HIV Infections Clinical Trials

Family-centered HIV Care, Viral Suppression and Retention in HIV-positive Children, Swaziland

FAM-CARE
Start date: September 13, 2017
Phase: N/A
Study type: Interventional

The study will evaluate the effect of implementing a family-centered care (FAM-CARE) program (where all HIV-positive family members are seen together as a unit and receive care together) on viral suppression and retention in HIV-positive children <15 years through enrollment of a prospective cohort of 660 HIV-positive children and their caregivers at sites that were randomized to either implement the family-care program (intervention sites) or continue the current standard of care (control sites).

NCT ID: NCT03392805 Recruiting - HIV-1-infection Clinical Trials

Infectious Diseases and Movement Program: Study of the Effects of Physical Activity on HIV Infection

PRIMO
Start date: January 1, 2016
Phase: N/A
Study type: Interventional

exercise and physical activity can have an anti-inflammatory effect, while there is evidence that a sedentary lifestyle could be the basis for the development of systemic inflammation and increased cardiovascular risk. The primary objective is to assess whether regular physical activity is able to induce a decrease in systemic immune-activation in HIV positive patients.

NCT ID: NCT03387397 Recruiting - Clinical trials for HIV Infection Primary

Assessing Differential Adherence to Medications and Quality of Life Among People Living With HIV and Comorbidities

TEAMH
Start date: December 12, 2017
Phase: N/A
Study type: Interventional

The investigators propose to utilize quantitative and qualitative methodology to better understand the impact of multiple drug use (polypharmacy) on medication adherence as well as the driving forces behind differential adherence in people living with HIV (PLWH) with comorbidities. Since the clinical relevance of differential adherence to antiretroviral therapy (ART) medication has already been demonstrated and associated with virologic failure and a more rapid progression to AIDS and death, it is imperative to understand the driving forces behind differential adherence (selective drug taking) and its impact on treatment outcomes in PLWH with comorbidities. Moreover, the use of technology to improve medication adherence is receiving much attention, and there are several smartphone applications that send medication reminders and generate personalized text messages to further motivate users. This type of technology could be particularly beneficial to patients who are managing multiple medications for multiple conditions. To this end, the investigators propose to use the medication adherence smartphone-based application, 'Technology for Engagement And Management of Health (TEAMH) to track both medication adherence and medication side effects in real-time among PLWH with comorbidities. TEAMH is an interactive health care information technology system that is not only patient-centered in that it encourages patient engagement in health care self-management, but also offers significant cost savings by directly connecting patients with their health care providers allowing providers to quickly address any health issue that may arise, thus potentially avoiding costly hospitalizations later on.

NCT ID: NCT03383211 Recruiting - HIV Infections Clinical Trials

Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers

IMMUNEO
Start date: June 16, 2017
Phase: N/A
Study type: Observational

Maternal infections affect the basal immune status of neonates. One of the possible mechanism is the fetomaternal microchimerism, in which some cells and active substances are exchanged bi-directionally between maternal and fetal circulation through placenta. Even in the absence of a direct (vertical) transmission of pathogens to fetuses, certain infections make the neonates more prone to allergies and some adverse events of early vaccinations. We postulate that the basal immune status of neonates born to HIV and LTBI infected mothers is primed by gestational exposure to immunological active molecules, which could results in an altered response to early BCG vaccination. Transcripts expression identified by RNA sequencing are compared between sets of mother-child and their respective umbilical cord blood, and between groups of infected and non-infected pairs.

NCT ID: NCT03382418 Recruiting - HIV Infections Clinical Trials

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

Start date: December 27, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV vaccine (gp145 C.6980) with aluminum hydroxide adjuvant in healthy, HIV-1-uninfected adults in the United States.

NCT ID: NCT03369327 Recruiting - Clinical trials for Human Immunodeficiency Virus

Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus

HIV200
Start date: January 1, 2017
Phase: Phase 3
Study type: Interventional

In a multi-center study 200 patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) will be treated with a fixed-dose combination pill combined of 400 mg sofosbuvir and 30, 60, or 90 mg of daclatasvir - depending on the particular antiretroviral treatment (ART) being used by the patient. The treatment duration will be 12 weeks for subjects without cirrhosis and 24 weeks for those with cirrhosis.

NCT ID: NCT03368053 Recruiting - Clinical trials for Infection, Human Immunodeficiency Virus

Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)

Start date: December 14, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the long-term persistence of binding antibody responses against V1V2 and gp120 in subjects who were vaccinated with the envelope glycoprotein 120 (gp120)-negative factor (Nef)Tat/ Adjuvant System 01B (AS01B) (GSKSB732461) vaccine candidate. Other immune parameters like the HIV-specific cluster of differentiation (CD4+) T cell and CD8+ T cell responses will also be evaluated.

NCT ID: NCT03367754 Recruiting - Clinical trials for Human Immunodeficiency Virus

A Single Dose of Pembrolizumab in HIV-Infected People

Start date: January 24, 2018
Phase: Phase 1
Study type: Interventional

Background: Human immunodeficiency virus (HIV) attacks the immune system. Some people with HIV have a low CD4+ T-cell count despite taking antiviral medicines that control HIV replication. These cells fight disease, so a low count makes it easier for people to become sick. Researchers want to see if a new drug can improve the immune system, including T cells. The drug is called pembrolizumab Objective: To see if pembrolizumab is safe to use in people with HIV who have a low CD4+ T cell count despite taking medcines that control HIV replication, and to see if it strengthens the immune system. Eligibility: People age 18 years or older with HIV who are taking antiretroviral drugs as treatment, have blood HIV levels below detection limits of commercial assays, and have a low CD4+ T-cell count (below 350 cells/mm3). Design: Participants will be screened with: Medical history Physical exam Heart, blood, and urine tests Sexually active participants must use 2 kinds of birth control. Participants will have leukapheresis. Blood will be removed through a needle in one arm. A machine will remove white blood cells. The rest of the blood will be returned into the other arm. Participants will have a baseline visit. They will have blood tests. They may have a pregnancy test. A needle will insert a thin plastic tube (IV) into an arm vein. The participants will get the study drug or a placebo through the IV for 30 minutes. They will be watched for a couple hours after. Participants will have 11 follow-up visits over the next 48 weeks. They will have a physical exam, vital signs, medical review, and blood tests. Participants may have another leukapheresis. Participants will be called every 12 weeks after their last follow-up visit to talk about how they feel and their health. Participation ends after the week 96 phone call. Sponsoring Institute: National Institute of Health Clinical Center